Intuitive Surgical (NASDAQ:ISRG) Shares Down 0.9% - Here's What Happened

Intuitive Surgical, Inc. (NASDAQ:ISRG - Get Free Report) fell 0.9% on Thursday . The company traded as low as $597.77 and last traded at $603.30. 287,679 shares were traded during mid-day trading, a decline of 83% from the average session volume of 1,693,671 shares. The stock had previously closed at $608.48.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ISRG shares. Erste Group Bank raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Tuesday, November 19th. Bernstein Bank boosted their price objective on Intuitive Surgical from $655.00 to $700.00 and gave the company an "overweight" rating in a research report on Monday, January 27th. Truist Financial raised their target price on Intuitive Surgical from $640.00 to $666.00 and gave the company a "buy" rating in a research note on Friday, January 24th. Piper Sandler reaffirmed an "overweight" rating and issued a $670.00 price objective (up previously from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Finally, UBS Group upped their target price on shares of Intuitive Surgical from $500.00 to $560.00 and gave the stock a "neutral" rating in a research report on Monday, January 27th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $613.10.

Intuitive Surgical Stock Performance

The stock has a market cap of $210.78 billion, a price-to-earnings ratio of 92.32, a price-to-earnings-growth ratio of 5.85 and a beta of 1.39. The company's 50 day simple moving average is $565.45 and its two-hundred day simple moving average is $525.60.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Myriam Curet sold 408 shares of the company's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total value of $240,618.00. Following the transaction, the executive vice president now directly owns 353 shares of the company's stock, valued at $208,181.75. This represents a 53.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Amal M. Johnson sold 4,635 shares of Intuitive Surgical stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $566.60, for a total value of $2,626,191.00. Following the sale, the director now owns 12,275 shares of the company's stock, valued at approximately $6,955,015. This represents a 27.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,348 shares of company stock valued at $3,587,582. 0.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ISRG. Atala Financial Inc acquired a new position in Intuitive Surgical during the fourth quarter worth $25,000. Hurley Capital LLC acquired a new position in shares of Intuitive Surgical during the 4th quarter valued at about $28,000. Berbice Capital Management LLC bought a new position in shares of Intuitive Surgical in the 4th quarter valued at approximately $26,000. Parvin Asset Management LLC bought a new position in shares of Intuitive Surgical in the 4th quarter valued at approximately $26,000. Finally, BankPlus Trust Department bought a new stake in Intuitive Surgical during the fourth quarter worth approximately $28,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.